Cargando…
PEDT-19 RECENT PROGRESS IN CHILDHOOD BRAIN TUMORS RESEARCH
The multidisciplinary standard of care for medulloblastoma, a typical pediatric malignant brain tumor of cerebellar primary origin, has been established by large RCTs in the United States. The results of the Phase III RCTs sponsored by Children's Oncology Group's for newly-diagnosed medull...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719344/ http://dx.doi.org/10.1093/noajnl/vdac167.041 |
_version_ | 1784843303108214784 |
---|---|
author | Terashima, Keita |
author_facet | Terashima, Keita |
author_sort | Terashima, Keita |
collection | PubMed |
description | The multidisciplinary standard of care for medulloblastoma, a typical pediatric malignant brain tumor of cerebellar primary origin, has been established by large RCTs in the United States. The results of the Phase III RCTs sponsored by Children's Oncology Group's for newly-diagnosed medulloblastoma in children 3 years of age and older, ACNS0331, which attempted radiotherapy reduction for the average-risk group, and ACNS0332, which attempted intensified treatment with carboplatin as a radiosensitizer and isotretinoin as an apoptosis inducer for high-risk group are discussed.It has recently been reported that some infantile glioma cells have activating fusion genes with tyrosine kinase receptor genes, including NTRK, and that TRK inhibitors are effective against these tumors, and two TRK inhibitors have been used with cancer genome panel tests as companion diagnostics, Two TRK inhibitors can now be available for glioma treatment in Japanese practice. The results of clinical trials on the efficacy of these targeting agents in brain tumors with NTRK mutations will be presented.CAR-T cell therapy was developed for GD2 following HER2, which had attracted attention as an immunotherapeutic target for pediatric glioma, and its efficacy was demonstrated in clinical trials. We will examine the results of clinical trials of this immunotherapy, a promising treatment for DMS/DIPG, the disease with absolutely poor prognosis with no effective drug therapy, although it is used in a small number of cases. |
format | Online Article Text |
id | pubmed-9719344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97193442022-12-06 PEDT-19 RECENT PROGRESS IN CHILDHOOD BRAIN TUMORS RESEARCH Terashima, Keita Neurooncol Adv Abstracts The multidisciplinary standard of care for medulloblastoma, a typical pediatric malignant brain tumor of cerebellar primary origin, has been established by large RCTs in the United States. The results of the Phase III RCTs sponsored by Children's Oncology Group's for newly-diagnosed medulloblastoma in children 3 years of age and older, ACNS0331, which attempted radiotherapy reduction for the average-risk group, and ACNS0332, which attempted intensified treatment with carboplatin as a radiosensitizer and isotretinoin as an apoptosis inducer for high-risk group are discussed.It has recently been reported that some infantile glioma cells have activating fusion genes with tyrosine kinase receptor genes, including NTRK, and that TRK inhibitors are effective against these tumors, and two TRK inhibitors have been used with cancer genome panel tests as companion diagnostics, Two TRK inhibitors can now be available for glioma treatment in Japanese practice. The results of clinical trials on the efficacy of these targeting agents in brain tumors with NTRK mutations will be presented.CAR-T cell therapy was developed for GD2 following HER2, which had attracted attention as an immunotherapeutic target for pediatric glioma, and its efficacy was demonstrated in clinical trials. We will examine the results of clinical trials of this immunotherapy, a promising treatment for DMS/DIPG, the disease with absolutely poor prognosis with no effective drug therapy, although it is used in a small number of cases. Oxford University Press 2022-12-03 /pmc/articles/PMC9719344/ http://dx.doi.org/10.1093/noajnl/vdac167.041 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstracts Terashima, Keita PEDT-19 RECENT PROGRESS IN CHILDHOOD BRAIN TUMORS RESEARCH |
title | PEDT-19 RECENT PROGRESS IN CHILDHOOD BRAIN TUMORS RESEARCH |
title_full | PEDT-19 RECENT PROGRESS IN CHILDHOOD BRAIN TUMORS RESEARCH |
title_fullStr | PEDT-19 RECENT PROGRESS IN CHILDHOOD BRAIN TUMORS RESEARCH |
title_full_unstemmed | PEDT-19 RECENT PROGRESS IN CHILDHOOD BRAIN TUMORS RESEARCH |
title_short | PEDT-19 RECENT PROGRESS IN CHILDHOOD BRAIN TUMORS RESEARCH |
title_sort | pedt-19 recent progress in childhood brain tumors research |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719344/ http://dx.doi.org/10.1093/noajnl/vdac167.041 |
work_keys_str_mv | AT terashimakeita pedt19recentprogressinchildhoodbraintumorsresearch |